Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial | Zendy

Sydney Lou Bonnick | Zendy; Tobias De Villiers | Zendy; Alberto Odio | Zendy; Santiago Palacios | Zendy; Roland Chapurlat | Zendy; Carolyn DaSilva | Zendy; Boyd B. Scott | Zendy; Celine Le Bailly De Tilleghem | Zendy; Albert Leung | Zendy; Deborah M. Gurner | Zendy

Open Access

Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial

Author(s) -

Sydney Lou Bonnick,

Tobias De Villiers,

Alberto Odio,

Santiago Palacios,

Roland Chapurlat,

Carolyn DaSilva,

Boyd B. Scott,

Celine Le Bailly De Tilleghem,

Albert Leung,

Deborah M. Gurner

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-2020

Subject(s) - medicine , femoral neck , osteoporosis , bone mineral , placebo , endocrinology , urology , trochanter , bone remodeling , type i collagen , creatinine , cathepsin k , bone density , n terminal telopeptide , alkaline phosphatase , osteocalcin , chemistry , pathology , osteoclast , alternative medicine , receptor , biochemistry , enzyme

Odanacatib (ODN) is a selective cathepsin K inhibitor being developed to treat osteoporosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research